tickdelta
Sign in

Tickdelta is free for now. Sign up and get Pro free

← Screener

Health care · Drug Wholesale · NYSE

CORCencora

Compare with peers → Embed
The 10-K against last year's

202 changes: 19 added, 19 removed, 160 reworded, 4 quiet changes

10-K Nov 25, 2025 vs Nov 26, 2024
Risk FactorsRedline ↓
29.5%
of the text changed · 13,523 words now
20.9%
of the text changed · 9,153 words now
Legal ProceedingsRedline ↓
36.2%
of the text changed · 2,982 words now
Accounting PoliciesRedline ↓
8.9%
of the text changed · 4,445 words now

10-K 0001140859-25-000131 (Nov 25, 2025) vs 10-K 0001140859-24-000177 (Nov 26, 2024)

The redline

The paragraph that changed most in each section

Marked against last year's 10-K: cut words struck through, new words highlighted and underlined.

Risk Factors 312 words changed in this paragraph; it is 46% similar to last year's version.
We believe that maintaining and enhancing our reputation is critical to our ability to expand and retain our customer base, strategic partnerships and other key relationships. Any negative publicity about us or our industry may adversely impact our business and operations. Furthermore, any actual or perceived failure to comply with ethical, social, regulatory, product, labor, health and safety, quality, accounting, or environmental requirements or standards could also jeopardize our reputation and potentially lead to various adverse actions, including litigation, audits, investigations, or adverse stakeholder action. Negative claims or publicity, including on social media, could adversely affect our reputation and business, regardless of their accuracy. Our reputation may also depend on the success of our environmental, social and governance ("ESG") initiatives, inclusive of sustainability, social impact and corporate responsibility, which responsibility initiatives that require Company-wide coordination and alignment. Risks associated with these initiatives include, without limitation, alignment among varying jurisdictions. For example, there continues to be an increased focus on ESG targets, goals and disclosure, including by governmental and nongovernmental organizations, organizations on corporate responsibility and sustainability-related actions, targets, and disclosures; increased costs and investment associated with sustainability efforts, corporate responsibility efforts (including supply chain due diligence); and increasing compliance obligations with laws related laws, regulations, and regulations. standards (including the Corporate Sustainability Reporting Directive and the Corporate Sustainability Due Diligence Directive in the EU). Given the varied and at times divergent views of different stakeholder groups, any action or inaction by us with respect to corporate responsibility initiatives may be perceived negatively by some stakeholders. Furthermore, the regulatory landscape surrounding corporate responsibility matters continues to evolve and remains uncertain. All of the foregoing could expose us to market, operational and execution costs or risks. risks, as well as litigation, audits, investigations, or adverse stakeholder action. Any ESG corporate responsibility or sustainability metrics that we currently or may in the future disclose, whether based on the standards that we set for ourselves or those set by third parties, may influence our reputation and the value of our brands. There is also increased continued focus, including by investors, customers, and other stakeholders, on ESG corporate responsibility matters, including with respect to the use of materials, climate change, certain materials and minerals, fleet electrification, sustainable packaging, emissions reporting, waste generation, supply chain, chain diligence, human capital, and health equity and worker safety. Our reputation could be damaged if we do not, or are perceived to not, not to, act responsibly in a way that is aligned with stakeholder expectations with respect to sustainability corporate responsibility matters, which could also have a material adverse effect on our business, financial position, results of operations, and cash flows. the Company.

Source: Item 1A, 10-K 0001140859-25-000131 vs Item 1A, 10-K 0001140859-24-000177

Legal Proceedings 299 words changed in this paragraph; it is 34% similar to last year's version.
In Maryland, a trial commenced on September 16, 2024 in a case filed by the Mayor and City Council of Baltimore in the Circuit Court for Baltimore City. On November 12, 2024, the jury returned a verdict finding ABDC (and another national distributor) liable for public nuisance and assessing approximately $274 million total in compensatory damages, approximately $74 million of which was assessed against ABDC. A second phase of the trial is scheduled to commence began on December 11, 2024 related to the City of Baltimore's Baltimore’s request for an abatement remedy, which will proceed remedy and proceeded as a bench trial. While On June 12, 2025, the judgment is not yet final, Court issued a ruling on the Company is evaluating next steps, including defendants’ post-trial motions relating to the first phase of the trial. The Court upheld the jury’s finding of liability, but granted the defendants a possible appeal. new trial on the extent of damages to correct certain errors and due to the excessive nature of the jury’s damages award. In the alternative, the Court granted remittitur, through which the Court reduced the compensatory damages assessed against ABDC to approximately $14.4 million. The $74 Court issued its ruling regarding the City of Baltimore’s request for abatement on August 8, 2025, assessing approximately $28 million against ABDC for abatement measures, bringing the overall monetary award assessed against ABDC to approximately $42.5 million. On August 14, 2025, the City of Baltimore informed the Court that it would accept the reduced damages award as reflected in the Court’s post-trial ruling, in lieu of a new trial. On September 2, 2025, the Court entered final judgment. In October 2025, ABDC (and the other national distributor) filed a notice of appeal to the Appellate Court of Maryland, and the City of Baltimore filed a notice of cross-appeal. In November 2025, both the City of Baltimore and ABDC (and the other national distributor) filed petitions for a writ of certiorari (bypass) with the Supreme Court of Maryland. If the Court grants the petitions, then the appeal will proceed directly in that Court, instead of in the Appellate Court. The $42.4 million is a component of the Company's $4.9 Company’s $4.3 billion litigation liability as of September 30, 2024 2025, as described below. above.

Source: Item 3, via Note 12 – Legal Matters and Contingencies, 10-K 0001140859-25-000131 vs Item 3, via Note 13 – Legal Matters and Contingencies, 10-K 0001140859-24-000177

MD&A 144 words changed in this paragraph; it is 36% similar to last year's version.
Interest expense, net decreased $71.9 increased $134.6 million, or 31.4%, 85.7%, from the prior fiscal year due to the increase in interest income expense, offset in part by an increase in interest income. The increase in interest expense was primarily due to the issuance of our $1.8 billion of senior notes in December 2024 and the decrease $1.5 billion variable-rate term loan, which we borrowed in interest expense. January 2025 to finance a portion of the RCA acquisition, increased revolving credit facility borrowings to cover short-term working capital needs, and the May 2025 issuance of our €1.0 billion of senior notes, offset in part by the repayment of our $500 million of senior notes that matured in March 2025. The increase in interest income was driven by higher investment interest rates and higher average investment cash balances in the current fiscal year 2025 in comparison to the prior fiscal year. The decrease in interest expense was primarily driven by a decrease in interest expense at our European distribution business primarily due to the September 2023 divestiture of our less-than-wholly-owned subsidiary in Egypt and decreased borrowings in Turkey. 2024.

Source: Item 7, 10-K 0001140859-25-000131 vs Item 7, 10-K 0001140859-24-000177

Accounting Policies 72 words changed in this paragraph; it is 68% similar to last year's version.
In November 2023, the Financial Accounting Standards Board ("FASB") (“FASB”) issued ASU Accounting Standards Update (“ASU”) No. 2023-07, "Segment “Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures ("ASU 2023-07")." (“ASU 2023-07”).” ASU 2023-07 requires public entities to disclose significant segment expenses on an annual and interim basis and to provide in interim periods all disclosures about a reportable segment's segment’s profit or loss that are currently required annually. ASU 2023-07 is effective for annual periods beginning after December 15, 2023 and interim periods beginning after December 15, 2024. Early adoption is permitted. The guidance should be applied retrospectively to all periods presented in the financial statements. The Company is currently evaluating adopted ASU 2023-07 and retrospectively reflected segment cost of goods sold and segment operating expenses in Note 14. The adoption of ASU 2023-07 had no impact on the impact of adopting this new accounting guidance. Company’s Consolidated Financial Statements.

Source: Item 8, Note 1 – Summary of Significant Accounting Policies, 10-K 0001140859-25-000131 vs Item 8, Note 1 – Summary of Significant Accounting Policies, 10-K 0001140859-24-000177

Every change, by type

Sentences and paragraphs added, removed or reworded

Sentences and paragraphs of COR's Risk Factors and MD&A, 10-K Nov 25, 2025 against 10-K Nov 26, 2024. Each links to the text at sec.gov.

RemovedRisk Factors
The closing of the variable prepaid forward transactions concerning our common stock by WBA could adversely affect prevailing market prices of our common stock.

Read it in 10-K Nov 26, 2024 at sec.gov ↗

RemovedRisk Factors
WBA has the right, but not the obligation, under the transactions contemplated by the Framework Agreement, dated March 18, 2013, and the Amended and Restated AmerisourceBergen Shareholders Agreement, dated June 1, 2021 (as amended, the "Shareholders Agreement"), to make certain additional investments in our common stock. WBA also has the right to sell any of the shares of our common stock that it has acquired so long as WBA has held the shares beyond the requisite dates specified in the Shareholders Agreement, subject to certain restrictions on the number of shares that may be sold at any given time. From May 2023 through the date of this Annual Report on Form 10-K, WBA has pledged 20.0 million shares of our common stock as collateral upon entering into separate variable pre-paid forward transactions. The closing of the variable pre-paid forward transactions could adversely affect prevailing market prices of our common stock. We could also encounter unforeseen costs, circumstances, or issues with respect to the transactions and collaboration that we anticipate pursuing with

Read it in 10-K Nov 26, 2024 at sec.gov ↗

RemovedRisk Factors
WBA. Many of these potential circumstances are outside of our control and any of them could result in increased costs, decreased revenue, decreased benefits and the diversion of management’s time and attention.

Read it in 10-K Nov 26, 2024 at sec.gov ↗

RemovedRisk Factors
Our businesses operate in a number of jurisdictions that have a higher business, operating, and regulatory risk profile than the United States, United Kingdom, and European Union jurisdictions. Such risks may include risks of violation of the United States’, the United Kingdom’s and other jurisdictions’ anti-corruption, anti-bribery, and international trade laws. Our results of operations and financial position may be adversely affected if we are not able to put in place effective financial

Read it in 10-K Nov 26, 2024 at sec.gov ↗

RemovedRisk Factors
controls and compliance policies to safeguard against such risks as part of our integration of businesses, including PharmaLex, RCA, and other acquisitions.

Read it in 10-K Nov 26, 2024 at sec.gov ↗

RemovedRisk Factors
Changes or uncertainty in U.S. policies or the policies of other countries and regions in which we do business, including any changes or uncertainty with respect to U.S. or international trade policies or tariffs, also can disrupt our global operations, as well as the operations of our customers and suppliers. Any disruption may inhibit our access to, or require us to spend more money to source, certain products or that we use in our operations. Any of these factors could adversely affect our business, financial position, results of operations, and cash flows.

Read it in 10-K Nov 26, 2024 at sec.gov ↗

RemovedRisk Factors
not have a material impact on us, either individually or in the aggregate, similar incidents or events in the future may materially impact our business, reputation or financial results.

Read it in 10-K Nov 26, 2024 at sec.gov ↗

RemovedRisk Factors
any customer that has a substantial amount owed to us could have a material adverse effect on our operating revenue and results of operations. As of September 30, 2024, our two largest trade receivable balances due from customers represented approximately 37% and 5% of our accounts receivable, net.

Read it in 10-K Nov 26, 2024 at sec.gov ↗

Show the other 7
RemovedRisk Factors
At the federal level, in the United States, the DSCSA establishes national traceability standards requiring drugs to be labeled and tracked at the bottle level, preempts state drug pedigree requirements, and required all supply-chain stakeholders to participate in an electronic, interoperable prescription drug traceability system by November 2023. In August 2023, however, the FDA established a stabilization period, which is set to expire on November 27, 2024, to allow trading partners to implement, troubleshoot and mature their electronic interoperable systems. The FDA expects trading partners to use this stabilization period to build and validate interoperable systems and processes, manage products and data, and ensure continuity of the supply chain and product availability to patients. In October 2024, the FDA announced that it would allow exemptions from the expiring stabilization period (and subsequent enforcement), extending the timelines for certain trading partners who have initiated electronic systems but continue to work toward addressing challenges around data exchange, quality and reliability. These exemptions apply to eligible wholesale distributors, including the Company, until August 27, 2025.

Read it in 10-K Nov 26, 2024 at sec.gov ↗

RemovedRisk Factors
Additionally, in 2024, the FTC issued a request for information to industry stakeholders to review the cause of and potential solutions to drug shortages. Responses were received from many stakeholders but no further action has been taken.

Read it in 10-K Nov 26, 2024 at sec.gov ↗

RemovedRisk Factors
In addition, various proposals have been advanced to permit the importation of drugs from other countries to provide lower cost alternatives to the products available in the United States. An example is the Safe Importation Action Plan ("SIP") that was released by HHS and the FDA on July 31, 2019, and that outlines two potential pathways to allow importation of certain drugs from foreign markets. Following the SIP framework, the FDA issued a final rule that allows importation of certain lower-cost prescription drugs from Canada. Under the rule, states or certain other non-federal governmental entities are permitted to submit importation program proposals to the FDA for review and authorization of two-year programs (with the opportunity to extend for two more years). While the final rule became effective on November 30, 2020, its implementation has been delayed and its impact is uncertain, in part because lawsuits have been filed challenging the government’s authority to promulgate it. Further, authorities in Canada have passed rules designed to safeguard the Canadian drug supply from shortages. Despite the ongoing litigation, on July 9, 2021, President Biden signed an Executive Order pertaining to drug pricing that

Read it in 10-K Nov 26, 2024 at sec.gov ↗

RemovedRisk Factors
directs the Commissioner of the FDA to work with states and Indian Tribes to facilitate the commercial importation of certain prescription drugs from Canada. If implemented, importation of drugs from Canada may materially and adversely affect our business. The regulatory and market implications of the final rule and guidance remain unknown. Proponents of drug reimportation may attempt to pass legislation that would directly allow reimportation under certain circumstances. Legislation or regulations allowing the reimportation of drugs, if enacted, could decrease the price that we receive for products and adversely affect our future revenues and prospects for profitability.

Read it in 10-K Nov 26, 2024 at sec.gov ↗

RemovedMD&A
On November 5, 2024, we entered into an agreement to acquire Retina Consultants of America ("RCA"). Under the terms of the agreement, we will acquire RCA for cash based on an enterprise value of approximately $4.6 billion, subject to a customary working capital and net-debt adjustment. RCA’s affiliated practices, physicians, and management will rollover a portion of their equity in RCA. After giving effect to the rollover, a cash capitalization of RCA that we intend to make, and the payment of transaction fees and expenses, our expected cash outlay at closing would be approximately $4.3 billion. At closing, we expect to hold approximately 85% ownership in RCA. The agreement also provides for the potential payment of up to $500 million in aggregate contingent consideration in fiscal 2027 and fiscal 2028, subject to the successful completion of certain predefined business objectives. We expect to fund the transaction through a combination of cash on hand and new debt financing and have obtained $3.3 billion in bridge financing commitments in connection with the transaction. The transaction is subject to the satisfaction of closing conditions, including receipt of required regulatory approvals.

Read it in 10-K Nov 26, 2024 at sec.gov ↗

RemovedMD&A
The quantitative impairment test for indefinite-lived intangibles other than goodwill (certain trademarks and trade names) consists of a comparison of the fair value of the indefinite-lived intangible asset to the carrying value of the asset as of the impairment testing date. We estimate the fair value of its indefinite-lived intangibles using the relief from royalty method, which is a widely used valuation technique for such assets. The fair value derived from the relief from royalty method is measured as the discounted cash flow savings realized from owning such indefinite-lived trademarks and trade names and not having to pay a royalty for their use.

Read it in 10-K Nov 26, 2024 at sec.gov ↗

Next Related parties →